QURE DEADLINE REMINDER: Berger Montague Reminds uniQure N.V. (QURE) Investors of Important Class Action Lawsuit Deadline

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified class period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Group 1: Lawsuit Details - The lawsuit targets investors who purchased uniQure securities from September 24, 2025, to October 31, 2025 [1][2]. - Investors have until April 13, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130, which is intended to treat Huntington's disease [3]. - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies [3]. Group 3: Stock Impact - Following the disclosure on November 3, 2025, that the FDA did not agree with the use of Phase I/II data for BLA submission, uniQure's stock plummeted over 49%, from $67.69 per share on October 31, 2025, to $34.29 per share [4].